FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter O'Dwyer

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Hyunseon Christine Kang; Stephen M Keefe; Peter J O'Dwyer; Keith T Flaherty; Daniel F Heitjan; Evan S Siegelman; Kay-See Tan; Mark A Rosen
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Keith T Flaherty; Reginald F Frye; Chetan Lathia; Maryann Redlinger; Mark Rosen; Lynn Schuchter; Peter J O'Dwyer
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Weijing Sun; Ursina R Teitelbaum; Millie Caparro; Bruce Giantonio; Daniel G Haller; Kristine Mykulowycz; Peter J O'Dwyer; Rajender Reddy; Mark Rosen; Abraham Shaked; Davendra Sohal; Michael C Soulen; Kim Olthoff
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter O'Dwyer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Hyunseon Christine Kang; Stephen M Keefe; Peter J O'Dwyer; Keith T Flaherty; Daniel F Heitjan; Evan S Siegelman; Kay-See Tan; Mark A Rosen
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
AJR. American journal of roentgenology 2013;200(1):120-6.
2011: Keith T Flaherty; Reginald F Frye; Chetan Lathia; Maryann Redlinger; Mark Rosen; Lynn Schuchter; Peter J O'Dwyer
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Cancer chemotherapy and pharmacology 2011;68(5):1111-8.
2011: Weijing Sun; Ursina R Teitelbaum; Millie Caparro; Bruce Giantonio; Daniel G Haller; Kristine Mykulowycz; Peter J O'Dwyer; Rajender Reddy; Mark Rosen; Abraham Shaked; Davendra Sohal; Michael C Soulen; Kim Olthoff
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Cancer 2011;117(14):3187-92.
2011: Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Science (New York, N.Y.) 2011;331(6024):1612-6.
2011: Weijing Sun; James M Metz; Maryann Gallagher; Peter J O'Dwyer; Bruce Giantonio; Richard Whittington; Daniel G Haller
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
Cancer chemotherapy and pharmacology 2011;67(3):621-7.
2010: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Inhibition of mutated, activated BRAF in metastatic melanoma.
The New England journal of medicine 2010;363(9):809-19.
2010: Weijing Sun; Mark Powell; Peter J O'Dwyer; Paul J Catalano; Rafat H Ansari; Al B Benson
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(18):2947-51.
2009: Crystal S Denlinger; Rebecca Blanchard; Lu Xu; Coen Bernaards; Samuel Litwin; Cynthia Spittle; Daniel J Berg; Susan McLaughlin; Maryann Redlinger; Andrew Dorr; Julie Hambleton; Scott Holden; Anne Kearns; Sara Kenkare-Mitra; Bert Lum; Neal J Meropol; Peter J O'Dwyer
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2009;65(1):97-105.
2009: David Casarett; Jessica M. Fishman; Hien L Lu; Peter J O'Dwyer; Frances K Barg; Mary D Naylor; David A Asch
The terrible choice: re-evaluating hospice eligibility criteria for cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(6):953-9.
2009: Esmé Finlay; Hien L Lu; Hope Henderson; Peter J O'Dwyer; David Casarett
Do phase 1 patients have greater needs for palliative care compared with other cancer patients?
Cancer 2009;115(2):446-53.
2008: Vandana Gupta-Abramson; Andrea B Troxel; Anoma Nellore; Kanchan Puttaswamy; Maryann Redlinger; Kathy Ransone; Susan J Mandel; Keith T Flaherty; Laurie A Loevner; Peter J O'Dwyer; Marcia S Brose
Phase II trial of sorafenib in advanced thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4714-9.
2008: Keith T Flaherty; Joan Schiller; Lynn Schuchter; Glenn Liu; David A Tuveson; Maryann Redlinger; Chetan Lathia; Chenghua Xia; Oana Petrenciuc; Sunil R Hingorani; Michael Jacobetz; Patricia Van Belle; David E Elder; Marcia S Brose; Barbara L Weber; Mark R Albertini; Peter J O'Dwyer
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4836-42.
2008: Irina A Vasilevskaya; Muthu Selvakumaran; Peter J O'Dwyer
Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin.
Molecular pharmacology 2008;74(1):246-54.
2008: Keith T Flaherty; Mark A Rosen; Daniel F Heitjan; Maryann L Gallagher; Brian Schwartz; Mitchell D Schnall; Peter J O'Dwyer
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Cancer biology & therapy 2008;7(4):496-501.
2008: David Casarett; Jessica M. Fishman; Peter J O'Dwyer; Frances K Barg; Mary Naylor; David A Asch
How should we design supportive cancer care? The patient's perspective.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1296-301.
2008: Muthu Selvakumaran; Kang-Shen Yao; Michael D Feldman; Peter J O'Dwyer
Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.
Biochemical pharmacology 2008;75(3):627-38.
2007: Christopher M Dolinsky; Najjia N Mahmoud; Rosemarie Mick; Weijing Sun; R W Whittington; Lawrence J Solin; Daniel G Haller; Bruce Giantonio; Peter J O'Dwyer; E F Rosato; Robert D Fry; James M Metz
Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.
Journal of surgical oncology 2007;96(3):207-12.
2007: Tatiana V Rakitina; Irina A Vasilevskaya; Peter J O'Dwyer
Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.
Biochemical pharmacology 2007;73(11):1715-26.
2007: Bruce Giantonio; Paul J Catalano; Neal J Meropol; Peter J O'Dwyer; Edith P Mitchell; Steven R Alberts; Michael A Schwartz; Al B Benson
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1539-44.
2007: Robert H Vonderheide; Keith T Flaherty; Magi Khalil; Molly S Stumacher; David L Bajor; Natalie A Hutnick; Patricia Sullivan; J Joseph Mahany; Maryann Gallagher; Amy Kramer; Stephanie J Green; Peter J O'Dwyer; Kelli L Running; Richard D Huhn; Scott J Antonia
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):876-83.
2006: S Biade; M Marinucci; Jonathan Schick; David Roberts; Gail Workman; E Helene Sage; Peter J O'Dwyer; Virginia A LiVolsi; Steven W Johnson
Gene expression profiling of human ovarian tumours.
British journal of cancer 2006;95(8):1092-100.
2006: Peter J O'Dwyer
The present and future of angiogenesis-directed treatments of colorectal cancer.
The oncologist 2006;11(9):992-8.
2006: Bruce Giantonio; D E Levy; Peter J O'Dwyer; Neal J Meropol; Paul J Catalano; Al B Benson
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(9):1399-403.
2006: Maria Luisa Veronese; Ari Mosenkis; Keith T Flaherty; Maryann Gallagher; James P Stevenson; Raymond R Townsend; Peter J O'Dwyer
Mechanisms of hypertension associated with BAY 43-9006.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1363-9.
2005: K Yao; J A Gietema; S Shida; Muthu Selvakumaran; X Fonrose; N B Haas; J Testa; Peter J O'Dwyer
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo.
British journal of cancer 2005;93(12):1356-63.
2005: Kangshen Yao; Seiichiro Shida; Muthu Selvakumaran; Robert Zimmerman; Ephraim Simon; Jonathan Schick; Naomi B Haas; Marge Balke; Howard Ross; Steven W Johnson; Peter J O'Dwyer
Macrophage migration inhibitory factor is a determinant of hypoxia-induced apoptosis in colon cancer cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7264-72.
2005: Irina A Vasilevskaya; Peter J O'Dwyer
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines.
Biochemical pharmacology 2005;70(4):580-9.
2005: Maria Luisa Veronese; Weijing Sun; Bruce Giantonio; Jesse Berlin; Justine Shults; L Davis; Daniel G Haller; Peter J O'Dwyer
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
British journal of cancer 2005;92(10):1846-9.
2005: Maria Luisa Veronese; Keith T Flaherty; Amy Kramer; Barbara A Konkle; Mark Morgan; James P Stevenson; Peter J O'Dwyer
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(5):497-501.
2005: David Roberts; Jonathan Schick; S Conway; S Biade; PB Laub; James P Stevenson; Thomas C Hamilton; Peter J O'Dwyer; Steven W Johnson
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.
British journal of cancer 2005;92(6):1149-58.
2005: Joshua H Bilenker; Keith T Flaherty; Mark Rosen; Lisa Davis; Maryann Gallagher; James P Stevenson; Weijing Sun; David Vaughn; Bruce Giantonio; Ross Zimmer; Mitchell D Schnall; Peter J O'Dwyer
Phase I trial of combretastatin a-4 phosphate with carboplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1527-33.
2004: Weijing Sun; Richard Whittington; Maryann Gallagher; Peter J O'Dwyer; Bruce Giantonio; James Metz; Daniel Haller
Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.
Oncology (Williston Park, N.Y.) 2004;18(14 Suppl 14):39-42.
2004: Joshua H Bilenker; James P Stevenson; M L Gallagher; David Vaughn; M B Cohen; Peter J O'Dwyer
Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days.
British journal of cancer 2004;91(2):213-8.
2004: Chu Won Nho; Peter J O'Dwyer
NF-kappaB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling.
The Journal of biological chemistry 2004;279(25):26019-27.
2004: Maria Luisa Veronese; Peter J O'Dwyer
Monoclonal antibodies in the treatment of colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(9):1292-301.
2004: Keith T Flaherty; James P Stevenson; Maryann Redlinger; Kenneth M Algazy; Bruce Giatonio; Peter J O'Dwyer
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
Cancer chemotherapy and pharmacology 2004;53(5):404-8.
2004: Joshua H Bilenker; James P Stevenson; Keith T Flaherty; Kenneth M Algazy; Kathy McLaughlin; Daniel G Haller; Bruce Giantonio; M Koehler; J E Garcia-Vargas; Peter J O'Dwyer
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
Cancer chemotherapy and pharmacology 2004;53(4):357-60.
2004: Maria Luisa Veronese; James P Stevenson; Weijing Sun; Maryann Redlinger; Kenneth M Algazy; Bruce Giantonio; Stephen Hahn; David Vaughn; Caroline Thorn; Alexander S Whitehead; Daniel G Haller; Peter J O'Dwyer
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(4):508-14.
2004: Bruce Giantonio; Christine Derry; Cecilia McAleer; Joseph J McPhillips; Peter J O'Dwyer
Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1282-8.
2004: Joseph A Sparano; Robert Gray; Bruce Giantonio; Peter J O'Dwyer; Robert L Comis
Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1206-11.
2004: Irina A Vasilevskaya; Tatiana V Rakitina; Peter J O'Dwyer
Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.
Molecular pharmacology 2004;65(1):235-43.
2003: Tatiana V Rakitina; Irina A Vasilevskaya; Peter J O'Dwyer
Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling.
Cancer research 2003;63(24):8600-5.
2003: James P Stevenson; Mark Rosen; Weijing Sun; Maryann Gallagher; Daniel G Haller; David Vaughn; Bruce Giantonio; Ross Zimmer; William P Petros; Michael Stratford; David Chaplin; Scott L Young; Mitchell D Schnall; Peter J O'Dwyer
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4428-38.
2003: Weijing Sun; James P Stevenson; Maryann L Gallagher; David Vaughn; Stephen M Hahn; Daniel G Haller; Marvin Cohen; Justin Kopit; Gilles Gallant; Peter J O'Dwyer
Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5221-7.
2003: Keith T Flaherty; James P Stevenson; Stephen M Hahn; Maryann Redlinger; Peter J O'Dwyer
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Cancer chemotherapy and pharmacology 2003;52(3):217-22.
2003: Tomoyuki Oe; Ye Tian; Peter J O'Dwyer; David W Roberts; Christopher J Bailey; Ian A Blair
Determination of the platinum drug cis-amminedichloro(2-methylpyridine)platinum(II) in human urine by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;792(2):217-27.
2003: Kang-Shen Yao; Peter J O'Dwyer
Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention.
Biochemical pharmacology 2003;66(1):15-23.
2003: Irina A Vasilevskaya; Tatiana V Rakitina; Peter J O'Dwyer
Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
Cancer research 2003;63(12):3241-6.
2003: Irina A Vasilevskaya; Peter J O'Dwyer
Role of Jun and Jun kinase in resistance of cancer cells to therapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(3):147-56.
2003: Peter J O'Dwyer; Steven W Johnson
Current status of oxaliplatin in colorectal cancer.
Seminars in oncology 2003;30(3 Suppl 6):78-87.
2003: Keith T Flaherty; James P Stevenson; Maryann Gallagher; Bruce Giantonio; Kenneth M Algazy; Weijing Sun; Daniel G Haller; Peter J O'Dwyer
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer.
Cancer 2003;97(8):1985-90.
2003: Haruka Itakura; David Vaughn; Daniel G Haller; Peter J O'Dwyer
Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.
The Journal of urology 2003;169(2):613.
2002: Peter J O'Dwyer; Al B Benson
Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Seminars in oncology 2002;29(5 Suppl 14):10-7.
2002: Weijing Sun; James P Stevenson; James M Gallo; Maryann Redlinger; Daniel Haller; Kenneth M Algazy; Bruce Giantonio; Hector Alila; Peter J O'Dwyer
Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(10):3100-4.
2002: James P Stevenson; Weijing Sun; Maryann Gallagher; Robert Johnson; David Vaughn; Lynn Schuchter; Kenneth M Algazy; Stephen Hahn; Nathan Enas; Diane Ellis; Donald Thornton; Peter J O'Dwyer
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2524-9.
2002: Thomas Malone; Paul J Catalano; Peter J O'Dwyer; Bruce Giantonio
High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experience.
Journal of the National Cancer Institute 2002;94(10):769-71.
2002: Bin Pan; Kang-Shen Yao; Brett P Monia; Nicholas Dean; Robert A McKay; Thomas C Hamilton; Peter J O'Dwyer
Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype.
Biochemical pharmacology 2002;63(9):1699-707.
2002: Jianguo Ma; Maureen Murphy; Peter J O'Dwyer; Eric Berman; Karin Reed; James M Gallo
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Biochemical pharmacology 2002;63(7):1219-28.
2002: Tomoyuki Oe; Ye Tian; Peter J O'Dwyer; David W Roberts; Michael D Malone; Christopher J Bailey; Ian A Blair
A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate.
Analytical chemistry 2002;74(3):591-9.
2001: Keith T Flaherty; James P Stevenson; Peter J O'Dwyer
Antisense therapeutics: lessons from early clinical trials.
Current opinion in oncology 2001;13(6):499-505.
2001: James P Stevenson; Maryann Redlinger; Leo A J Kluijtmans; Weijing Sun; Kenneth M Algazy; Bruce Giantonio; Daniel G Haller; Christine Hardy; Alexander S Whitehead; Peter J O'Dwyer
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(20):4081-7.
2001: Weijing Sun; James P Stevenson; Maryann Gallagher; Bruce Giantonio; Kenneth M Algazy; Daniel Haller; David Vaughn; B J Raskay; Peter J O'Dwyer
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
Cancer 2001;92(2):414-9.
2001: Peter J O'Dwyer; J Manola; F H Valone; L M Ryan; J D Hines; S Wadler; Daniel G Haller; Arbuck Susan; L M Weiner; Robert J Mayer; Al B Benson
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2413-21.
2001: Peter J O'Dwyer; James P Stevenson; Daniel G Haller; N Rotman; Bruce Giantonio
Follow-up of stage B and C colorectal cancer in the United States and France.
Seminars in oncology 2001;28(1 Suppl 1):45-9.
2001: Christine E Szarka; K S Yao; Gordon R Pfeiffer; Andrew Balshem; Samuel Litwin; Harold Frucht; Eric Goosenberg; Paul F Engstrom; Margie L Clapper; Peter J O'Dwyer
Chronic dosing of oltipraz in people at increased risk for colorectal cancer.
Cancer detection and prevention 2001;25(4):352-61.
2000: Peter J O'Dwyer; Christine E Szarka; J M Brennan; PB Laub; James M Gallo
Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4692-6.
2000: James P Stevenson; Maryann Redlinger; Weijing Sun; Daniel Haller; Peter J O'Dwyer
Irinotecan and UFT/leucovorin in patients with advanced cancers.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):91-2.
2000: Peter J O'Dwyer; James P Stevenson; Steven W Johnson
Clinical pharmacokinetics and administration of established platinum drugs.
Drugs 2000;59 Suppl 4():19-27.
1999: Peter J O'Dwyer; James P Stevenson; M Gallagher; A Cassella; I Vasilevskaya; Brett P Monia; Jon T Holmlund; F Andrew Dorr; Kang-Shen Yao
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3977-82.
1999: Irina A Vasilevskaya; Peter J O'Dwyer
Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells.
Cancer research 1999;59(16):3935-40.
1999: James P Stevenson; Kang-Shen Yao; M Gallagher; D Friedland; Edith P Mitchell; A Cassella; Brett P Monia; T Jesse Kwoh; R Yu; Jon T Holmlund; F Andrew Dorr; Peter J O'Dwyer
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2227-36.
1999: Peter J O'Dwyer; K Nelson; D E Thornton
Overview of phase II trials of MTA in solid tumors.
Seminars in oncology 1999;26(2 Suppl 6):99-104.
1999: James P Stevenson; D DeMaria; J Sludden; S B Kaye; L Paz-Ares; Louise B. Grochow; alexander mcdonald; K Selinger; Paul Wissel; Peter J O'Dwyer; Chris Twelves
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(3):339-44.
1999: James P Stevenson; D DeMaria; D Reilly; Jeremy Purvis; Martin A Graham; Graham Lockwood; M Drozd; Peter J O'Dwyer
Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule.
Cancer chemotherapy and pharmacology 1999;44(3):228-34.
1998: L Paz-Ares; R Kunka; D DeMaria; Jim Cassidy; M Alden; P Beranek; S Kaye; D Littlefield; D Reilly; S DePee; Paul Wissel; Chris Twelves; Peter J O'Dwyer
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
British journal of cancer 1998;78(10):1329-36.
1998: James P Stevenson; R M Scher; R Kosierowski; S C Fox; M Simmonds; Kang-Shen Yao; F Green; C Broom; Scott Z Fields; JB Krebs; Peter J O'Dwyer
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1358-62.
1998: P Calvert; Kang-Shen Yao; Thomas C Hamilton; Peter J O'Dwyer
Clinical studies of reversal of drug resistance based on glutathione.
Chemico-biological interactions 1998;111-112():213-24.
1998: Peter J O'Dwyer; James P Stevenson
Chemotherapy of advanced colorectal cancer.
Cancer treatment and research 1998;98():111-52.
1998: G R Weiss; Italo POggesi; Maurizio Rocchetti; D DeMaria; T Mooneyham; D Reilly; L V Vitek; F Whaley; E Patricia; Daniel Von Hoff; Peter J O'Dwyer
A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):53-9.
1997: Peter J O'Dwyer; M Clayton; T Halbherr; C B Myers; K s Yao
Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):783-91.
1997: Peter J O'Dwyer; S W Johnson; C Khater; A Krueger; Y Matsumoto; Thomas C Hamilton; Kang-Shen Yao
The chemopreventive agent oltipraz stimulates repair of damaged DNA.
Cancer research 1997;57(6):1050-3.
1997: Richard E Greenberg; RR Bahnson; David P Wood Jr; S J Childs; C Bellingham; M Edson; M H Bamberger; G D Steinberg; M Israel; Trevor W Sweatman; Bruce Giantonio; Peter J O'Dwyer
Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder.
Urology 1997;49(3):471-5.
1997: Kang-Shen Yao; A Hageboutros; P Ford; Peter J O'Dwyer
Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment.
Molecular pharmacology 1997;51(3):422-30.
1997: C A Johnson; Deborah Kilpatrick; R von Roemeling; Corey Langer; Martin A Graham; Dennis Greenslade; G Kennedy; Eileen Keenan; Peter J O'Dwyer
Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):773-80.
1997: A Hageboutros; Gary R Hudes; F Greene; F P LaCreta; J Brennan; Peter J O'Dwyer
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Investigational new drugs 1997;15(2):139-45.
1996: Corey J Langer; M Millenson; Peter J O'Dwyer; R Kosierowski; R Alexander; Samuel Litwin; Cecilia McAleer; C A Bonjo; Robert F Ozols
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Seminars in oncology 1996;23(6 Suppl 16):35-41.
1996: Peter J O'Dwyer; P B Laub; D DeMaria; M Qian; D Reilly; Bruce Giantonio; A L Johnston; E Y Wu; L Bauman; N J Clendeninn; James M Gallo
Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1685-92.
1996: Peter J O'Dwyer; Christine E Szarka; Kang-Shen Yao; T C Halbherr; Gordon R Pfeiffer; F Green; J M Gallo; J Brennan; Harold Frucht; E B Goosenberg; Thomas C Hamilton; Samuel Litwin; Andrew Balshem; Paul F Engstrom; Margie L Clapper
Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz.
The Journal of clinical investigation 1996;98(5):1210-7.
1996: Peter J O'Dwyer; R P Perez; Kang-Shen Yao; A K Godwin; Thomas C Hamilton
Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
Biochemical pharmacology 1996;52(1):21-7.
1996: Michael A Bookman; W P McGuire; D Kilpatrick; Eileen Keenan; W M Hogan; S W Johnson; Peter J O'Dwyer; eric rowinsky; H H Gallion; Robert F Ozols
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1895-902.
1996: Kang-Shen Yao; A K Godwin; C Johnson; Peter J O'Dwyer
Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment.
Cancer research 1996;56(8):1731-6.
1996: P A Ford; Arbuck Susan; C Minniti; L L Miller; D DeMaria; Peter J O'Dwyer
Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
European journal of cancer (Oxford, England : 1990) 1996;32A(4):631-5.
1996: C K Obasaju; S W Johnson; André Rogatko; D Kilpatrick; J M Brennan; Thomas C Hamilton; Robert F Ozols; Peter J O'Dwyer; James M Gallo
Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):549-52.
1996: C W Li; W G Negendank; K A Padavic-Shaller; Peter J O'Dwyer; J Murphy-Boesch; Truman R Brown
Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(2):339-45.
1996: R M Scher; R Kosierowski; C Lusch; R Alexander; S Fox; I Redei; F Green; B Raskay; K Amfoh; P F Engstrom; Peter J O'Dwyer
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
Investigational new drugs 1996;13(4):347-54.
1996: C P Schröder; A K Godwin; Peter J O'Dwyer; Kenneth D Tew; Thomas C Hamilton; Robert F Ozols
Glutathione and drug resistance.
Cancer investigation 1996;14(2):158-68.
1996: Peter J O'Dwyer; Thomas C Hamilton; F P LaCreta; James M Gallo; D Kilpatrick; T Halbherr; J Brennan; Michael A Bookman; J Hoffman; R C Young; R L Comis; Robert F Ozols
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):249-56.
1996: A Hageboutros; Gary R Hudes; J Brennan; F Green; J Hoffman; F P LaCreta; J Colofiore; D S Martin; Robert F Ozols; Peter J O'Dwyer
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Cancer chemotherapy and pharmacology 1996;37(3):229-34.
1995: James M Gallo; J Brennan; Thomas C Hamilton; T Halbherr; P B Laub; Robert F Ozols; Peter J O'Dwyer
Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Cancer research 1995;55(20):4507-11.
1995: Kang-Shen Yao; A K Godwin; S W Johnson; Robert F Ozols; Peter J O'Dwyer; Thomas C Hamilton
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.
Cancer research 1995;55(19):4367-74.
1995: R P Perez; S W Johnson; L M Handel; Peter J O'Dwyer; Thomas C Hamilton
Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells.
Gynecologic oncology 1995;58(3):312-8.
1995: Corey J Langer; J C Leighton; R L Comis; Peter J O'Dwyer; Cecilia McAleer; C A Bonjo; P F Engstrom; Samuel Litwin; S Johnson; Robert F Ozols
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Seminars in oncology 1995;22(4 Suppl 9):18-29.
1995: Corey J Langer; J C Leighton; R L Comis; Peter J O'Dwyer; Cecilia McAleer; C A Bonjo; P F Engstrom; Samuel Litwin; Robert F Ozols
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1860-70.
1995: Corey J Langer; J Leighton; Cecilia McAleer; R Comis; Peter J O'Dwyer; Robert F Ozols
Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Seminars in oncology 1995;22(3 Suppl 6):64-9.
1995: M Qian; Peter J O'Dwyer; James M Gallo
High-performance liquid chromatographic method for the determination of AG-331, a novel anti-cancer agent, in human serum and urine using solid-phase extraction and photodiode-array detection.
Journal of chromatography. B, Biomedical applications 1995;666(2):307-14.
1995: Peter J O'Dwyer; Thomas C Hamilton; Kang-Shen Yao; Kenneth D Tew; Robert F Ozols
Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs.
Hematology/oncology clinics of North America 1995;9(2):383-96.
1995: Kang-Shen Yao; Peter J O'Dwyer
Involvement of NF-kappa B in the induction of NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C.
Biochemical pharmacology 1995;49(3):275-82.
1995: Kang-Shen Yao; M Clayton; Peter J O'Dwyer
Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia.
Journal of the National Cancer Institute 1995;87(2):117-22.
1995: N B Haas; Russell J Schilder; S Nash; Louis M Weiner; R C Catalano; Robert F Ozols; Peter J O'Dwyer
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.
Investigational new drugs 1995;13(3):229-33.
1995: Margaret von Mehren; Bruce Giantonio; Cecilia McAleer; Russell J Schilder; J McPhillips; Peter J O'Dwyer
Phase I trial of ilmofosine as a 24 hour infusion weekly.
Investigational new drugs 1995;13(3):205-10.
1995: A Hageboutros; André Rogatko; E M Newman; Cecilia McAleer; J Brennan; F P LaCreta; Gary R Hudes; Robert F Ozols; Peter J O'Dwyer
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Cancer chemotherapy and pharmacology 1995;35(3):205-12.
1994: F P Lacreta; J M Brennan; Thomas C Hamilton; Robert F Ozols; Peter J O'Dwyer
Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(6):835-42.
1994: Kang-Shen Yao; S Xanthoudakis; T Curran; Peter J O'Dwyer
Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia.
Molecular and cellular biology 1994;14(9):5997-6003.
1994: F P Lacreta; J M Brennan; S L Nash; R L Comis; Kenneth D Tew; Peter J O'Dwyer
Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.
The Journal of pharmacology and experimental therapeutics 1994;270(3):1186-91.
1994: Peter J O'Dwyer; Kang-Shen Yao; P Ford; A K Godwin; M Clayton
Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells.
Cancer research 1994;54(12):3082-7.
1994: N B Haas; F P LaCreta; J Walczak; Gary R Hudes; J M Brennan; Robert F Ozols; Peter J O'Dwyer
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Cancer research 1994;54(5):1220-6.
1994: Peter J O'Dwyer; J D Moyer; M Suffness; S D Harrison; R Cysyk; T C Hamilton; J Plowman
Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
Cancer research 1994;54(3):724-9.
1994: Kang-Shen Yao; M Clayton; Peter J O'Dwyer
Interaction of heat and hypoxia in modulating transcription of DT diaphorase in human colon adenocarcinoma cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(2):125-31.
1994: Peter J O'Dwyer; F P LaCreta; N B Haas; T Halbherr; Harold Frucht; E Goosenberg; Kang-Shen Yao
Clinical, pharmacokinetic and biological studies of topotecan.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S46-52.
1994: I Redei; F Green; John P Hoffman; Louis M Weiner; R Scher; Peter J O'Dwyer
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
Investigational new drugs 1994;12(4):319-21.
1994: Peter J O'Dwyer
Biochemical modulation as an approach to reversal of antimetabolite resistance.
Cancer treatment and research 1994;73():201-16.
1993: Thomas C Hamilton; Peter J O'Dwyer; Robert F Ozols
Platinum analogues in preclinical and clinical development.
Current opinion in oncology 1993;5(6):1010-6.
1993: K Hamaguchi; A K Godwin; M Yakushiji; Peter J O'Dwyer; Robert F Ozols; Thomas C Hamilton
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Cancer research 1993;53(21):5225-32.
1993: J M Brennan; Peter J O'Dwyer; Robert F Ozols; F P LaCreta
High-performance liquid chromatographic determination of the S- and R-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine.
Journal of chromatography 1993;620(1):121-8.
1993: Peter J O'Dwyer; L Panting; F P LaCreta; Margie L Clapper
SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma.
Biochemical pharmacology 1993;46(7):1251-6.
1993: Peter J O'Dwyer; F P LaCreta; J Walczak; T Cox; Samuel Litwin; J P Hoffman; M Zimny; R L Comis
Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.
British journal of cancer 1993;68(4):756-66.
1993: Robert F Ozols; Peter J O'Dwyer; Thomas C Hamilton
Clinical reversal of drug resistance in ovarian cancer.
Gynecologic oncology 1993;51(1):90-6.
1993: K Yao; A K Godwin; Robert F Ozols; Thomas C Hamilton; Peter J O'Dwyer
Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Cancer research 1993;53(16):3662-6.
1993: N B Haas; J B Hines; Gary R Hudes; N Johnston; Robert F Ozols; Peter J O'Dwyer
Phase I trial of 5-fluorouracil by 24-hour infusion weekly.
Investigational new drugs 1993;11(2-3):181-5.
1993: Corey J Langer; N Rosenblum; M Hogan; S Nash; P Bagchi; F P LaCreta; R Catalano; R L Comis; Peter J O'Dwyer
Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach.
Cancer chemotherapy and pharmacology 1993;32(3):204-8.
1993: Louis M Weiner; Gary R Hudes; J Kitson; J Walczak; P Watts; Samuel Litwin; Peter J O'Dwyer
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Cancer immunology, immunotherapy : CII 1993;36(3):185-90.
1992: Peter J O'Dwyer; Gary R Hudes; J Walczak; Russell J Schilder; F LaCreta; B Rogers; I Cohen; C Kowal; L Whitfield; R A Boyd
Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
Cancer research 1992;52(24):6746-53.
1992: Peter J O'Dwyer; F P LaCreta; Russell J Schilder; S Nash; Cecilia McAleer; L L Miller; Gary R Hudes; Robert F Ozols
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(8):1352-8.
1992: R P Perez; S L Nash; Robert F Ozols; R L Comis; Peter J O'Dwyer
Phase II study of amonafide in advanced and recurrent sarcoma patients.
Investigational new drugs 1992;10(2):99-101.
1992: A K Godwin; A Meister; Peter J O'Dwyer; C S Huang; Thomas C Hamilton; Mary E Anderson
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(7):3070-4.
1992: Peter J O'Dwyer; Thomas C Hamilton; R C Young; F P LaCreta; N Carp; Kenneth D Tew; K Padavic; R L Comis; Robert F Ozols
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
Journal of the National Cancer Institute 1992;84(4):264-7.
1992: Brian Leyland-Jones; B R Davies; K Clagett-Carr; D Shoemaker; D Macfarlane; C Fortner; Peter J O'Dwyer; Gisele Sarosy; Brenda J Foster; H G Chun
Patient treatment on a compassionate basis: documentation of high adverse drug reaction rate.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(1):59-62.
1992: E Rosvold; Russell J Schilder; J Walczak; S M DiFino; P J Flynn; T K Banerjee; W J Heim; P F Engstrom; Robert F Ozols; Peter J O'Dwyer
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Cancer chemotherapy and pharmacology 1992;29(4):305-8.
1991: Corey J Langer; S Nash; R Catalano; N G Rosenblum; W M Hogan; R L Comis; Peter J O'Dwyer
Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma.
Gynecologic oncology 1991;43(3):242-6.
1991: Peter J O'Dwyer; F LaCreta; S Nash; P W Tinsley; Russell J Schilder; Margie L Clapper; Kenneth D Tew; L Panting; Samuel Litwin; R L Comis
Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
Cancer research 1991;51(22):6059-65.
1991: F P LaCreta; J M Brennan; P W Tinsley; Peter J O'Dwyer
High-performance liquid chromatographic determination of ethacrynic acid in human plasma.
Journal of chromatography 1991;571(1-2):271-6.
1991: Peter J O'Dwyer; Gary R Hudes; J Colofiore; J Walczak; J Hoffman; F P LaCreta; R L Comis; D S Martin; Robert F Ozols
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Journal of the National Cancer Institute 1991;83(17):1235-40.
1991: Gary R Hudes; F LaCreta; J Walczak; P Tinsley; Samuel Litwin; R L Comis; Peter J O'Dwyer
Pharmacokinetic study of trimetrexate in combination with cisplatin.
Cancer research 1991;51(12):3080-7.
1991: Peter J O'Dwyer; F LaCreta; Paul F Engstrom; R Peter; L Tartaglia; D Cole; Samuel Litwin; J DeVito; D Poplack; R J DeLap
Phase I/pharmacokinetic reevaluation of thioTEPA.
Cancer research 1991;51(12):3171-6.
1991: R P Perez; Peter J O'Dwyer; L M Handel; Robert F Ozols; Thomas C Hamilton
Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
International journal of cancer. Journal international du cancer 1991;48(2):265-9.
1991: Peter J O'Dwyer; F P LaCreta; J P Daugherty; M Hogan; N G Rosenblum; J L O'Dwyer; R L Comis
Phase I pharmacokinetic study of intraperitoneal etoposide.
Cancer research 1991;51(8):2041-6.
1991: P W Tinsley; Peter J O'Dwyer; F P LaCreta
Chromatographic analysis of methylmercaptopurine riboside in human plasma and urine.
Journal of chromatography 1991;564(1):303-9.
1991: Peter J O'Dwyer; F LaCreta; M Hogan; N Rosenblum; J L O'Dwyer; R L Comis
Pharmacologic study of etoposide and cisplatin by the intraperitoneal route.
Journal of clinical pharmacology 1991;31(3):253-8.
1991: Peter J O'Dwyer; A R Paul; Gary R Hudes; J Walczak; Robert F Ozols; R L Comis
Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
Investigational new drugs 1991;9(1):65-7.
1991: Peter J O'Dwyer; Corey J Langer; J Walczak; Michael H Levy; K Padavic-Shaller; Gary R Hudes; Samuel Litwin; R L Comis
Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1589-93.
1990: Robert F Ozols; Peter J O'Dwyer; Thomas C Hamilton; R C Young
The role of glutathione in drug resistance.
Cancer treatment reviews 1990;17 Suppl A():45-50.
1990: Peter J O'Dwyer; A R Paul; J Walczak; Louis M Weiner; Samuel Litwin; R L Comis
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(9):1497-503.
1990: Peter J O'Dwyer
Biochemical modulation of 5-fluorouracil by PALA.
Cancer investigation 1990;8(2):261-2.
1990: Peter J O'Dwyer; M J Cornfeld; R Peter; R L Comis
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
Cancer chemotherapy and pharmacology 1990;27(2):131-4.
1990: Peter J O'Dwyer
The role of low-dose PALA in biochemical modulation.
Pharmacology & therapeutics 1990;48(3):371-80.
1989: Peter J O'Dwyer; R L Comis
Schedule as a determinant of cytotoxic drug activity.
Current opinion in oncology 1989;1(2):174-8.
1989: P W Tinsley; Peter J O'Dwyer; F P LaCreta
High-performance liquid chromatographic analysis of N,N',N"-triethylenethiophosphoramide in human plasma.
Journal of chromatography 1989;495():318-23.
1989: Peter J O'Dwyer; S A King; E Eisenhauer; Jean L Grem; D F Hoth
Hypersensitivity reactions to deoxycoformycin.
Cancer chemotherapy and pharmacology 1989;23(3):173-5.
1988: Peter J O'Dwyer; S A King; J Plowman; C K Grieshaber; D F Hoth; Brian Leyland-Jones
Pyrazole: preclinical reassessment.
Investigational new drugs 1988;6(4):305-10.
1988: Jean L Grem; S A King; Peter J O'Dwyer; Brian Leyland-Jones
Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
Cancer research 1988;48(16):4441-54.
1988: Peter J O'Dwyer; Bruce D Cheson; Brian Leyland-Jones; S A King; D F Hoth
Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia.
Oncology (Williston Park, N.Y.) 1988;2(6):17-23, 26-7.
1988: Peter J O'Dwyer; B Wagner; Brian Leyland-Jones; R E Wittes; Bruce D Cheson; D F Hoth
2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
Annals of internal medicine 1988;108(5):733-43.
1987: S A King; M Suffness; Brian Leyland-Jones; D F Hoth; Peter J O'Dwyer
Indicine N-oxide: clinical use of a pyrrolizidine alkaloid.
Cancer treatment reports 1987;71(5):517-23.
1987: Peter J O'Dwyer; D Shoemaker; D S Zaharko; C Grieshaber; J Plowman; Thomas H Corbett; Frederick A Valeriote; S A King; J Cradock; D F Hoth
Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
Cancer chemotherapy and pharmacology 1987;19(1):6-10.
1987: Brian Leyland-Jones; Peter J O'Dwyer; D F Hoth; R E Wittes
Methodology for the rational development of methotrexate analogs in the clinic.
NCI monographs : a publication of the National Cancer Institute 1987;(5):93-7.
1987: Peter J O'Dwyer; B H Wagner; D F Hoth; Brian Leyland-Jones
5-Methyltetrahydrohomofolate.
Investigational new drugs 1987;5(3):215-8.
1987: Peter J O'Dwyer; R J DeLap; S A King; A J Grillo-Lopez; D F Hoth; Brian Leyland-Jones
Trimetrexate: clinical development of a nonclassical antifolate.
NCI monographs : a publication of the National Cancer Institute 1987;(5):105-9.
1986: Peter J O'Dwyer; S A King; D F Hoth; M Suffness; Brian Leyland-Jones
Homoharringtonine--perspectives on an active new natural product.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(10):1563-8.
1985: Brenda J Foster; K Clagett-Carr; Peter J O'Dwyer; Brian Leyland-Jones
Hypoglycemia: not an important side effect of mitoguazone.
Cancer treatment reports 1985;69(11):1340.
1985: Peter J O'Dwyer; D D Shoemaker; J Plowman; J Cradock; A Grillo-Lopez; Brian Leyland-Jones
Trimetrexate: a new antifol entering clinical trials.
Investigational new drugs 1985;3(1):71-5.
1984: Peter J O'Dwyer; D D Shoemaker; H N Jayaram; D G Johns; D A Cooney; S Marsoni; L Malspeis; J Plowman; J P Davignon; R D Davis
Tiazofurin: a new antitumor agent.
Investigational new drugs 1984;2(1):79-84.
1983: D D Shoemaker; Peter J O'Dwyer; S Marsoni; J Plowman; J P Davignon; R D Davis
Spiromustine: a new agent entering clinical trials.
Investigational new drugs 1983;1(4):303-8.